Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel

In a large cohort of United States healthcare personnel without prior coronavirus disease 2019 (COVID-19) infection, 94 382 doses of messenger RNA (mRNA) COVID-19 vaccine were administered to 49 220 individuals. The adjusted vaccine effectiveness following 2 doses of each of the 2 available brands o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clinical infectious diseases Ročník 73; číslo 6; s. e1376
Hlavní autoři: Swift, Melanie D, Breeher, Laura E, Tande, Aaron J, Tommaso, Christopher P, Hainy, Caitlin M, Chu, Haitao, Murad, M Hassan, Berbari, Elie F, Virk, Abinash
Médium: Journal Article
Jazyk:angličtina
Vydáno: 15.09.2021
ISSN:1537-6591, 1537-6591
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract In a large cohort of United States healthcare personnel without prior coronavirus disease 2019 (COVID-19) infection, 94 382 doses of messenger RNA (mRNA) COVID-19 vaccine were administered to 49 220 individuals. The adjusted vaccine effectiveness following 2 doses of each of the 2 available brands of mRNA vaccine exceeded 96%.In a large cohort of United States healthcare personnel without prior coronavirus disease 2019 (COVID-19) infection, 94 382 doses of messenger RNA (mRNA) COVID-19 vaccine were administered to 49 220 individuals. The adjusted vaccine effectiveness following 2 doses of each of the 2 available brands of mRNA vaccine exceeded 96%.
AbstractList In a large cohort of United States healthcare personnel without prior coronavirus disease 2019 (COVID-19) infection, 94 382 doses of messenger RNA (mRNA) COVID-19 vaccine were administered to 49 220 individuals. The adjusted vaccine effectiveness following 2 doses of each of the 2 available brands of mRNA vaccine exceeded 96%.In a large cohort of United States healthcare personnel without prior coronavirus disease 2019 (COVID-19) infection, 94 382 doses of messenger RNA (mRNA) COVID-19 vaccine were administered to 49 220 individuals. The adjusted vaccine effectiveness following 2 doses of each of the 2 available brands of mRNA vaccine exceeded 96%.
Author Breeher, Laura E
Chu, Haitao
Berbari, Elie F
Hainy, Caitlin M
Swift, Melanie D
Murad, M Hassan
Tande, Aaron J
Tommaso, Christopher P
Virk, Abinash
Author_xml – sequence: 1
  givenname: Melanie D
  surname: Swift
  fullname: Swift, Melanie D
– sequence: 2
  givenname: Laura E
  surname: Breeher
  fullname: Breeher, Laura E
– sequence: 3
  givenname: Aaron J
  surname: Tande
  fullname: Tande, Aaron J
– sequence: 4
  givenname: Christopher P
  surname: Tommaso
  fullname: Tommaso, Christopher P
– sequence: 5
  givenname: Caitlin M
  surname: Hainy
  fullname: Hainy, Caitlin M
– sequence: 6
  givenname: Haitao
  surname: Chu
  fullname: Chu, Haitao
– sequence: 7
  givenname: M Hassan
  surname: Murad
  fullname: Murad, M Hassan
– sequence: 8
  givenname: Elie F
  surname: Berbari
  fullname: Berbari, Elie F
– sequence: 9
  givenname: Abinash
  surname: Virk
  fullname: Virk, Abinash
BookMark eNpVjstOwzAURC1UJJ4rfuAuyyIQO07SLKO0QCWgqIVuqxvnGoyCXey0Un-ObyM8FrAYzSxmjuaIDayzxNgZjy94XCSXyjS9sE4yvscOeZrkUZYWfPAnH7CjEF7jmPNRnB6yj4nWpDqzJUshgNNw1zvZZ_Iwvy-hct5Z3Bq_CTA2gTAQiJgXMKxmy-k44sU5LFEp08-hfEZjQwcL2pInKNWmI5hTWBuPnfM7WOxs490b_cMKGC7K-SKq3DIS5zC134ecBWMB--aL893XsRvCtntR2JMfyAdnLbUnbF9jG-j014_Z09XksbqJbmfX06q8jZQUsosyKTONXKPO4kwknIq4zgRPiZpESq5HeS2xTnVSi4KjKrAhLQgl73tU1CSO2fCHu_bufUOhW72ZoKht0ZLbhJVI-SgXMstH4hOUnXpH
CitedBy_id crossref_primary_10_3390_vaccines9090989
crossref_primary_10_1111_hex_13751
crossref_primary_10_3390_vaccines10071125
crossref_primary_10_3389_fpsyt_2022_859884
crossref_primary_10_1016_j_ajem_2022_01_066
crossref_primary_10_15585_mmwr_mm7021e3
crossref_primary_10_1093_cid_ciab918
crossref_primary_10_1007_s00103_022_03607_x
crossref_primary_10_3390_vaccines10030469
crossref_primary_10_4103_2773_0344_329027
crossref_primary_10_1017_ash_2024_389
crossref_primary_10_3390_biomedicines10092063
crossref_primary_10_1001_jamanetworkopen_2022_8071
crossref_primary_10_3390_cancers17071246
crossref_primary_10_1038_s43856_022_00207_3
crossref_primary_10_2217_cer_2022_0069
crossref_primary_10_1093_ofid_ofac178
crossref_primary_10_3390_vaccines10111896
crossref_primary_10_1016_j_mayocp_2022_10_007
crossref_primary_10_1016_j_cmi_2021_11_023
crossref_primary_10_3390_vaccines9121489
crossref_primary_10_1093_cid_ciac235
crossref_primary_10_1136_bmj_n1943
crossref_primary_10_3390_vaccines10020157
crossref_primary_10_7326_M21_3509
crossref_primary_10_1136_bmjmed_2021_000040
crossref_primary_10_1093_ofid_ofad172
crossref_primary_10_1016_j_idnow_2024_104886
crossref_primary_10_1093_aje_kwad046
crossref_primary_10_1038_s41577_021_00592_1
crossref_primary_10_1016_j_gaceta_2022_03_002
crossref_primary_10_1128_aem_00128_23
crossref_primary_10_1016_j_lana_2021_100134
crossref_primary_10_1073_pnas_2108909118
crossref_primary_10_3390_pharmaceutics13111810
crossref_primary_10_1213_ANE_0000000000005858
crossref_primary_10_1093_cid_ciab739
crossref_primary_10_1186_s40249_021_00915_3
crossref_primary_10_1111_irv_13023
crossref_primary_10_1186_s12879_022_07702_x
crossref_primary_10_3390_vaccines10101590
crossref_primary_10_1093_ofid_ofad161
crossref_primary_10_1017_ash_2021_195
crossref_primary_10_3389_fimmu_2022_855311
crossref_primary_10_1038_s41408_021_00594_1
crossref_primary_10_3390_vaccines10030393
crossref_primary_10_3390_vaccines10030350
crossref_primary_10_1017_ice_2021_399
crossref_primary_10_1016_j_mayocp_2021_10_005
crossref_primary_10_1093_infdis_jiab570
crossref_primary_10_1371_journal_pone_0267824
ContentType Journal Article
Copyright The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Copyright_xml – notice: The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
DBID 7X8
DOI 10.1093/cid/ciab361
DatabaseName MEDLINE - Academic
DatabaseTitle MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1537-6591
GroupedDBID ---
..I
.2P
.I3
.ZR
08P
0R~
29B
2WC
36B
4.4
48X
53G
5GY
5RE
5VS
5WD
6J9
70D
7X8
AABZA
AACGO
AACZT
AAJKP
AAMVS
AANCE
AAOGV
AAPNW
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAVAP
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPLY
ABPQP
ABPTD
ABQLI
ABQNK
ABTLG
ABVGC
ABWST
ABXVV
ABZBJ
ACGFO
ACGFS
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFRAH
AFXAL
AFYAG
AGINJ
AGKEF
AGQXC
AGSYK
AGUTN
AHGBF
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQKUS
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CDBKE
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
H13
H5~
HAR
HW0
HZ~
IOX
J21
JLS
JSG
JXSIZ
KAQDR
KBUDW
KOP
KSI
KSN
L7B
MHKGH
MJL
ML0
N9A
NGC
NOMLY
NOYVH
NU-
O9-
OAUYM
OAWHX
OCZFY
ODMLO
ODZKP
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
P6G
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
RD5
ROX
ROZ
RUSNO
RW1
RXO
SJN
TCURE
TEORI
TJX
TMA
TR2
W8F
X7H
YAYTL
YKOAZ
YXANX
~91
~S-
ID FETCH-LOGICAL-c424t-6446fa1faf606231e90b6215eed3441f87b4ab5f3b291ac9adef2ea4190be9be2
IEDL.DBID 7X8
ISICitedReferencesCount 35
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000729810700020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1537-6591
IngestDate Tue Sep 30 22:48:44 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c424t-6446fa1faf606231e90b6215eed3441f87b4ab5f3b291ac9adef2ea4190be9be2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8135611
PQID 2518724678
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2518724678
PublicationCentury 2000
PublicationDate 2021-09-15
PublicationDateYYYYMMDD 2021-09-15
PublicationDate_xml – month: 09
  year: 2021
  text: 2021-09-15
  day: 15
PublicationDecade 2020
PublicationTitle Clinical infectious diseases
PublicationYear 2021
SSID ssj0011805
Score 2.6021006
Snippet In a large cohort of United States healthcare personnel without prior coronavirus disease 2019 (COVID-19) infection, 94 382 doses of messenger RNA (mRNA)...
SourceID proquest
SourceType Aggregation Database
StartPage e1376
Title Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel
URI https://www.proquest.com/docview/2518724678
Volume 73
WOSCitedRecordID wos000729810700020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxELaAItRLy1NQHhokDu3Baux11vYJrVKqVqKhSiDKrbLX4xIJ7ZZu0p_Hb2O8cRshLkjcLcureX3z2G8Y-zBwZmhlUDwEXXAVteQWfeDaJPI24UThexLXz3o8NvO5Pc8Fty6PVd76xN5Rh7ZONfJDisNGSzJr8_HqJ09bo1J3Na_QuM-2CoIySav1fNNFEKYfYSSj1rwcWpH_z6Mk_rAmUdPH-6IUf3nhPrQc7_7vox6znQwqoVprwRN2D5un7NFZbps_Y7_WHMXZsUEb4SxRhqeCHkzGFYwSjYG7WVyvOjhad2yAQraF_dGX2ekRF_YAZq5Ol3VQXboFYUqYIlkBQlWvlgiTTcceppkE4Y9rJexPq8mUj9oZlwdwmmfAGlg04Ojkd0oD0sNO7ubR4LxPBhr88Zx9O_70dXTC8-IGXiuplpwwVhmdiC5SekQAEu3Al4QtKB4XBL-i0V45P4ykB1a42rqAUaJTBE48Wo_yBXvQtA2-ZOCxKDFgGBgMSjpnta1VoQxG4UoX4yv2_lYyF2QYqdvhGmxX3cVGNnv_cOY125ZpWiUthxi-YVuRjB_fsof1zXLRXb_r9eo3HyXZ6g
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effectiveness+of+Messenger+RNA+Coronavirus+Disease+2019+%28COVID-19%29+Vaccines+Against+Severe+Acute+Respiratory+Syndrome+Coronavirus+2+%28SARS-CoV-2%29+Infection+in+a+Cohort+of+Healthcare+Personnel&rft.jtitle=Clinical+infectious+diseases&rft.au=Swift%2C+Melanie+D&rft.au=Breeher%2C+Laura+E&rft.au=Tande%2C+Aaron+J&rft.au=Tommaso%2C+Christopher+P&rft.date=2021-09-15&rft.issn=1537-6591&rft.eissn=1537-6591&rft.volume=73&rft.issue=6&rft.spage=e1376&rft_id=info:doi/10.1093%2Fcid%2Fciab361&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon